Comparative Pharmacology
Head-to-head clinical analysis: LONSURF versus XOSPATA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LONSURF versus XOSPATA.
LONSURF vs XOSPATA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LONSURF (trifluridine and tipiracil) is a combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil. Trifluridine incorporates into DNA and inhibits cell proliferation, while tipiracil increases trifluridine exposure by inhibiting its degradation by thymidine phosphorylase.
Gilteritinib is a tyrosine kinase inhibitor that inhibits FLT3 (FMS-like tyrosine kinase 3) receptor signaling, including FLT3-ITD and FLT3-TKD mutations, leading to apoptosis in leukemic cells.
Adults: 35 mg/m2 orally twice daily on days 1-5 and 8-12 of each 28-day cycle.
120 mg orally once daily.
None Documented
None Documented
Trifluridine: terminal half-life approximately 1.4-2.1 hours; tipiracil: terminal half-life approximately 2-3 hours. Clinical context: short half-lives necessitate twice-daily dosing on Days 1-5 and 8-12 of a 28-day cycle.
Terminal half-life 9.1 hours (range 4.4–16.1 hours); supports once-daily dosing.
Primarily renal: tipiracil is excreted unchanged in urine (approximately 50% of dose); trifluridine is eliminated via metabolism and renal excretion (as metabolites and unchanged drug). Fecal elimination accounts for <3% of total clearance.
Fecal (64%) and renal (16%) as metabolites; <1% unchanged in urine.
Category C
Category C
Antineoplastic
Antineoplastic